Alector Inc (NASDAQ: ALEC) is a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases. It generates no product revenue, operating instead on collaboration and funding arrangements with partners such as GSK. Its lead clinical asset, nivisnebart (formerly AL101/GSK4527226), is a monoclonal antibody designed to elevate progranulin (PGRN) levels in the brain, co-developed with GSK for early Alzheimer's disease and potentially Parkinson's disease. Wholly owned preclinical programs include AL137, a brain-penetrant anti-amyloid beta antibody for Alzheimer's disease; AL050, a GCase enzyme replacement therapy for Parkinson's disease and Lewy body dementia; and brain-penetrant siRNA programs targeting tau, alpha-synuclein, and NLRP3. Alector's platform combines antibody-brain carrier (ABC) technology, iPSC-based assays, biomarker-driven patient selection, and genetics-validated target identification. As of the 10-K filed February 25, 2026, all programs remain in clinical or preclinical development with no approved products.

Revenue model

Collaboration revenue from partnership arrangements, primarily with GSK for co-development of nivisnebart. No product revenue as of the 10-K filed February 25, 2026.

Products and services

Nivisnebart (AL101/GSK4527226): clinical-stage anti-PGRN monoclonal antibody for Alzheimer's disease and Parkinson's disease, co-developed with GSK. AL137: preclinical brain-penetrant anti-amyloid beta antibody for Alzheimer's disease. AL050: preclinical GCase enzyme replacement therapy for Parkinson's disease and Lewy body dementia. Brain-penetrant siRNA programs targeting tau (Alzheimer's disease), alpha-synuclein (Parkinson's disease), and NLRP3 (multiple neurodegenerative conditions). Proprietary antibody-brain carrier (ABC) technology platform.

Customers and end markets

Patients with neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, frontotemporal dementia, Lewy body dementia, and neuronal ceroid lipofuscinosis. Collaboration partner: GSK.

Value-chain role

Drug discovery and clinical development. Pre-commercial stage; no manufacturing or commercial sales as of the 10-K filed February 25, 2026.

Geographic exposure

Headquartered in the United States. Clinical and commercial planning references the United States and European Union as target markets per the 10-K filed February 25, 2026.

Source: SEC 10-K, filed 2026-02-25

Industry: Biological Products, (No Diagnostic Substances) Peers: AnaptysBio Inc Anavex Life Sciences Corp CTI BIOPHARMA CORP Dyne Therapeutics, Inc RAPT Therapeutics, Inc. INTERCEPT PHARMACEUTICALS, INC. iTeos Therapeutics, Inc. Sorrento Therapeutics, Inc. Y-mAbs Therapeutics, Inc.